Medical Crossfire®: The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

Welcome and Introductions

Module 1: How Do You Choose Between First-Line Endocrine Options for HR+/HER2– Metastatic Breast Cancer?

Module 2: How Are Biomarkers Driving Treatment Selection and Sequencing in the Second Line and Beyond for Endocrine-Sensitive HR+/HER2– mBC?

Module 3: How Are You Integrating and Sequencing Antibody-Drug Conjugates for Endocrine-Resistant HR+/HER2– Metastatic Breast Cancer?

Module 4: What Can We Look Forward to for HR+/HER2– Metastatic Breast Cancer?